Balance Sheet

Cash Flow Statement

Acquisitions Amortization of Deferred Charges Amortization of Deferred Charges Amortization of Goodwill Amortization of Goodwill Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Deferred Taxes Depreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - Common Dividends Paid - Common Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased

Daily Values

Growth Metrics

Definitive Healthcare (DH) Cash from Restructuring (2024 - 2025)

Definitive Healthcare filings provide 2 years of Cash from Restructuring readings, the most recent being $243000.0 for Q4 2025.

On a quarterly basis, Cash from Restructuring rose 26.56% to $243000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $595000.0, a 51.98% decrease, with the full-year FY2025 number at $595000.0, down 51.98% from a year prior.
Cash from Restructuring hit $243000.0 in Q4 2025 for Definitive Healthcare, up from $160000.0 in the prior quarter.
In the past five years, Cash from Restructuring ranged from a high of $1.0 million in Q2 2024 to a low of $160000.0 in Q3 2025.